Phase I Orally administered 14C-AZD2171 in patients with solid metastatic tumors

Study identifier:D8480C00019

ClinicalTrials.gov identifier:NCT00503412

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Open Label, Non-randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients with Solid Metastatic Tumours

Medical condition

advanced solid metastatic tumor

Phase

Phase 1

Healthy volunteers

Study drug

AZD2171

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 30 Nov 2005

Primary Completion Date: -

Study Completion Date: 31 May 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2025 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Sutton, United Kingdom

Arms	Assigned Interventions

"There is no result for the study"

Documents available

CSR-D8480C00019.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Nick Botwood

AstraZeneca